The Application Effect of Low-dose Apatinib Combined with FOLFOX Regimen on Advanced Colorectal Cancer and the Influence of Related Tumor Marker

HAN Hengchang; SHEN Jianyu; CUI Junzhao

doi:10.16458/j.cnki.1007-0893.2024.20.027

Abstract：Objective To explore the efficacy of low-dose apatinib combined with calcium folinate+oxaliplatin+5-fluorouracil(FOLFOX)regimen in the treatment of advanced colorectal cancer and the impact of serum related tumor marker levels.Methods A total of 80 patients with advanced colorectal cancer admitted to Yuzhou People's Hospital from March 2020 to March 2022 were selected as the study subjects and divided into an observation group and a control group using the lottery method,with 40 cases in each group.The control group received FOLFOX chemotherapy,while the observation group received low-dose apatinib combined with FOLFOX chemotherapy.The clinical efficacy,survival period and rate,incidence of adverse reactions,changes in serum tumor markers,quality of life and cancer-related fatigue before and after treatment between two groups of patients were compared.Results The disease control rate,objective response rate,median overall survival,median progression-free survival,1-year survival rate and 2-year survival rate in observation group were significantly higher than those in control group,with statistical significance(P<0.05).After treatment,the serum levels of cyclooxygenase-2(COX-2),carcinoembryonic antigen(CEA),matrix metalloproteinase-2(MMP-2)and carbohydrate antigen 199(CA199)in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the WHOQOL-BREF score of the observation group was higher than that of the control group,and the CRF score was lower than that of the control group,with statistical significance(P<0.05).Conclusion The combination of low-dose apatinib and FOLFOX regimen can improve the clinical efficacy of advanced colorectal cancer,enhance its survival and long-term survival rates,and reduce the serum tumor marker levels of patients.It has high safety,improves the quality of life of patients,and reduces the degree of cancer-related fatigue.